Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment by Brunello, Nicoletta et al.
 1
 
 
 
Social phobia: diagnosis and epidemiology, 
neurobiology and pharmacology, 
comorbidity and treatment 
 
 
N. Brunello, J.A den Boer, L.L Judd, S. Kasper, J.E Kelsey, M. Lader, Y. Lecrubier, J.P Lepine, R.B Lydiard, J. 
Mendlewicz, S.A Montgomery, G. Racagni, M.B Stein, H.-U Wittchen 
 
 
 
 
 
 
 
Abstract 
 Social phobia is a common disorder associated with significant psychosocial impairment, 
representing a substantial public health problem largely determined by the high prevalence, and the 
lifelong chronicity. Social phobia starts in early childhood or adolescence and is often comorbid with 
depression, other anxiety disorders, alcohol and substance abuse or eating disorders. This cascade of 
comorbidity, usually secondary to social phobia, increases the disability associated with the condition. 
The possibility that social phobia may be a trigger for later developing comorbid disorders directs 
attention to the need for early effective treatment as a preventive measure. 
 The most recent drug class to be investigated for the psychopharmacological treatment of social 
phobia is the SSRI group for which there is growing support. The other drug classes that have been 
evaluated are monoamine oxidase inhibitors (MAOIs), benzodiazepines, and beta-blockers. The SSRIs 
represent a new and attractive therapeutic choice for patients with generalized social phobia. Recently 
the first, large scale, placebo-controlled study to assess the efficacy of drug treatment in generalized 
social phobia has been completed with paroxetine. Paroxetine was more effective in reducing the 
symptoms than placebo and was well tolerated. Many now regard SSRIs as the drugs of choice in 
social phobia because of their effectiveness and because they avoid the problems of treatment with 
benzodiazepines or classical MAOIs. 
Keywords 
 Social phobia;  
 Anxiety disorders;  
 Comorbidity;  
 SSRI;  
 Paroxetine 
 2
1. What is social phobia? 
 Social phobia is an anxiety disorder with varying degrees of severity. This condition is 
characterised by clinically significant anxiety reactions and extreme discomfort occurring in 
anticipation of or upon exposure to social settings, including performance and test situations. Social 
phobia can interfere with one’s social or career development leaving the patient socially isolated and, 
in some cases, unable to pursue intimate relationships and career fulfilment. 
 Related to increasingly stringent and more detailed diagnostic criteria for social phobia over the 
past two decades, there is some variation in epidemiological findings across studies. The National 
Comorbidity Survey in the US found social phobia to be the third most common psychiatric disorder, 
after major depression and alcohol dependence (Kessler et al., 1994). The study of Weiller et al. 
(1996) also found it to be the third most common disorder in primary care after depression and GAD. 
Nevertheless, social phobia remains one of the least well recognised and understood mental disorders.  
 The Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) (American 
Psychiatric Association, 1994) defines social phobia as ‘a marked and persistent fear of one or more 
social performance situations in which the person is exposed to unfamiliar people or to possible 
scrutiny by others. The individual fears that he or she will act in a way (or show anxiety symptoms) 
that will be humiliating or embarrassing’. The fear must be seen as excessive or unreasonable by the 
patient, lead to avoidance of feared situations or cause anticipatory anxiety, and significantly interfere 
with the patient’s social or occupational life. The fear or avoidance must not be the direct effect of any 
substance or general medical condition.  
 The reticence that is characteristic of social phobia inhibits many patients from volunteering 
relevant information (e.g. to a physician, teacher, etc.). In addition, some patients who have built their 
lives around avoiding their feared situations may also have trouble recognising and reporting areas of 
functioning in which they are impaired. In other words, some patients see their functional limitation as 
‘just the way I am’. For these reasons, it is important to be systematic and comprehensive in 
evaluating social phobia symptoms and the extent of related impairment. Because of the broad 
spectrum of disability related to social phobia, many experts feel today that it would be preferable to 
refer to social phobia with the DSM-IV synonym, ‘social anxiety disorder’. 
 This consensus statement summarizes current knowledge of this disorder and emerging data on its 
treatment. 
2. Diagnosis and epidemiology 
 The first problem in establishing a diagnosis of social phobia is the issue of diagnostic thresholds. 
Distinguishing social phobia from normal shyness is a quantitative issue related to the level of distress 
and impairment associated with social fears. Because shyness is usually self-defined, it probably 
represents a more heterogeneous group than social phobia, including cases that would not meet 
clinical criteria for the disorder. In a recent telephone survey of a community sample, Stein et al. 
(1994) examined the effects of different thresholds for determining caseness in persons with social 
anxiety. Different thresholds led to variations in prevalence from 1.9% to 18.7%, depending on the 
stringency of the definitions of distress and impairment (Kessler et al., 1998 and Wittchen et al., 
1998). 
 Social phobia is characterised by the presence of physical, cognitive, and behavioural symptoms. 
The physical symptoms reported by many persons with social phobia include sweating, shaking, 
blushing, palpitations, nausea, and diarrhoea. In studies using physiologic measures, patients with 
social phobia show the increased arousal typical of most anxious subjects on exposure to their feared 
stimuli (e.g. increased heart rate and blood pressure and decreased habituation of skin conductance 
responses) (Beidel et al., 1985 and Turner et al., 1986). 
 At the other end of the severity spectrum, another dilemma that appears frequently in the 
differential diagnosis is avoidant personality disorder, with which social phobia commonly overlaps. 
Avoidant personality disorder as defined in the DSM-IV appears to be a more severe form of social 
phobia, however the diagnosis of avoidant personality disorder can be misleading and has not been 
supported by recent data and these two diagnostic groups do not appear to differ qualitatively in any 
substantive way (Schneier, 1995). 
 By following a series of relatively simple rules, the diagnosis of social phobia, for the most part, 
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should be fairly straightforward. The A criterion, or the gateway symptom in the diagnosis of social 
phobia is marked and persistent fear of social or performance situations in which embarrassment may 
occur (Table 1). 
 
 
 
 
 
 
 
 
 Another diagnostic distinction is made in social phobia by subclassifying social phobia into 
generalised or the more circumscribed or non-generalised type. In generalised social phobia, which is 
the most debilitating, the patient fears most social interactions and situations. The circumscribed type 
of social phobia usually involves fears of public performance or speaking when scrutiny is inevitable. 
 The most difficult differential diagnostic consideration for the clinician in identifying the patient 
with social phobia is the potential confusion with agoraphobia with and without panic attacks (and 
panic disorder). The reason for this confusion is that agoraphobics can experience fear reactions and 
will also avoid specific social situations. However, the agoraphobic avoidance is based primarily on 
the fact that the patients fear having a panic attack or fear the loss of control in a crowd or social 
situation from which the patient may not easily escape. They may also fear a social situation in which 
exit from this situation is embarrassing, difficult or impossible. Compared to patients with panic 
disorder, social phobics do not have uncued spontaneous panic attacks, however, their anxiety in 
social phobia sometimes takes the form of symptoms that resemble panic attacks with a tendency of a 
higher frequency of blushing, muscle twitching, stammering, and dry mouth, while they are less likely 
to experience dizziness or respiratory symptoms (Amies et al., 1983, Solyom et al., 1986 and Reich et 
al., 1988). 
 A careful history will often allow the physician to distinguish the social phobic by eliciting the 
core clinical feature (A criterion symptom), that the main concern is fear of scrutiny or humiliation in 
social situations where scrutiny and evaluation may be present. In general, social phobics do not avoid 
social situations because they fear having a panic attack or where escape is difficult; their avoidance 
invariably involves fear of evaluation and scrutiny. A significant number of patients who answer 
advertisements or are referred to psychiatric clinics with diagnoses of panic disorder have proved, on 
careful diagnostic examination, to be social phobics (Bisserbe et al., 1996). It is highly probable that 
clinicians may be under-recognising and under-diagnosing social phobia in their practices (Amies et 
al., 1983, Liebowitz et al., 1985a and Bisserbe et al., 1996). 
 All epidemiological studies show that social phobia is among the most frequent disorders 
encountered in the general population (Schneier et al., 1992a; Wacker et al., 1992 and Magee et al., 
1996) or in primary care (Weiller et al., 1996). The prevalence of social phobia has been studied in 
several epidemiological studies throughout the world in the past decade (Wittchen et al., 
1996 and Wittchen et al., 1998). Many of the earliest studies were based on DSM-III criteria assessed 
with the Diagnostic Interview Schedule (DIS) (Robins et al., 1981a and Robins et al., 1981b). The 
Epidemiologic Catchment Area (ECA) program found the lifetime (LT) prevalence of social phobia to 
be 2.8% (Regier et al., 1990). Similar estimates were obtained in community surveys carried out in 
Munich (2.5%) (Wittchen et al., 1992), Edmonton (1.7%) (Bland et al., 1988), Zurich (3.2%) (Angst 
and Dobler-Mikola, 1991), New Zealand (3.9%) (Wells et al., 1989) and Paris (4.1%) (Lepine and 
Lellouch, 1995). These prevalences could be regarded as fairly conservative estimates, as the version 
of the DIS used in these surveys assessed social fears as part of the simple phobia section, covering 
only a very limited range of those social fears clinically relevant for the evaluation of social phobics 
(Davidson et al., 1994, Walker and Stein, 1995, Magee et al., 1996 and Wittchen and Beloch, 1996). 
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 This underestimation problem was corrected in the successor to the DIS, the World Health 
Organization’s Composite International Diagnostic Interview (CIDI) (World Health Organization, 
1990) by developing a social phobia diagnostic module that comprehensively evaluates all the types of 
social fears specified in DSM-III-R and DSM-IV. Community epidemiologic surveys using the CIDI 
have obtained considerably higher estimates of social phobia prevalence than earlier studies, including 
a 13.3% LT prevalence in the National Comorbidity Survey (Magee et al., 1996) and 16.1% in Basel, 
Switzerland (Wacker et al., 1992). Although some part of these higher prevalences than in the earlier 
DIS surveys could be due to differences in sample composition or field procedures, the much more 
comprehensive screening questions for social fears has been held responsible for most of the increase 
(Wittchen and Beloch, 1996). So far no epidemiological data have been published reporting prevalence 
estimates and describing in more detail specific characteristics, such as what proportion of cases suffer 
from fairly isolated social phobia (e.g. performance anxiety) as well as more generalized forms, how 
they differ from each other, and what type of cognitive and behavioral correlates are most frequently 
observed in early and later stages of this disorder. 
 At this point prevalence estimates for DSM-IV social phobia are only available from one general 
population study of 3021 subjects aged 14 to 24 on the basis of the CIDI, indicating somewhat 
considerably lower rates than DSM-III-R studies (Wittchen et al., 1998). This difference in prevalence 
estimates is probably due to a higher threshold for severity demanded by the version of the CIDI used 
in this study rather than by differences between DSM-III-R and DSM-IV criteria. Despite the 
prevalence differences, there is good agreement with regard to the psychosocial correlates and risk 
factors associated with social phobia in the earlier DIS studies and more recent CIDI studies. They all 
agree that rates of social phobia are slightly higher among women than men, are considerably more 
frequent in younger as compared to older age cohorts, and are significantly associated with lower 
socioeconomic status (Bourdon et al., 1988, Bourdon, 1993 and Magee et al., 1996). Most studies also 
report that the majority of social phobics have onset in childhood or adolescence (Burke et al., 1990) 
and usually go untreated (Burns, 1980 and Schneier et al., 1992a; Ross, 1993 and Magee et al., 1996). 
Social phobia appears in these surveys to be a risk factor for poor school performance, school dropout, 
poor work performance, unemployment, and alcohol abuse (Mullaney and Trippet, 
1979 and Liebowitz et al., 1985a; Davidson et al., 1993a; Wittchen and Beloch, 1996).  
 Secondary analysis of a number of these surveys shows, consistent with clinical studies (Liebowitz 
et al., 1985a), that social phobics have a significantly increased risk (as compared to people with no 
social phobia) of having other anxiety disorders, major depressive as well as substance use disorders 
(Merikangas et al., 1996, Lepine and Pelissolo, 1996 and Lecrubier and Weiller, 1997), which seem to 
occur mostly secondary in time to the development of social phobia. However, the findings on 
temporality of disorders should be taken cautiously, due to the retrospective assessment strategies used 
in these studies. From an etiological perspective, several prospective studies in children (Biederman et 
al., 1990 and Rosenbaum et al., 1992) also suggest on the basis of prospective studies in children, that 
‘behavioral inhibition’ (long latency to approach a stranger in behavioral studies), a fairly well-defined 
temperamental construct, might be a powerful antecedent for the later development of social phobia 
and, perhaps, other anxiety disorders. 
 The clinical course of social phobia can be chronic, however clinical observations suggest 
considerable variations, thus more research is needed. Patients often enter treatment later in life, 
frequently reporting suffering from severe symptoms for many years before seeking treatment. Thus, 
the combination of a very early onset, together with a chronic lifetime course indicates that social 
phobia is often associated with many decades of social impairment and disability. 
 Social phobics have been reported to have significantly lower levels of educational achievement in 
terms of years of school completed. More than half of the social phobics who have been studied were 
sufficiently impaired in their educational achievement that they were unable to complete high school. 
Even more striking, is that social phobics are often in the lowest two quartiles of socioeconomic status 
in the society, with over 70% of social phobics falling in the lower half of the population in terms of 
socioeconomic achievement. Schneier et al. (1994) have reported that 22.3% of their sample of US 
patients with pure social phobia are currently on welfare, implying that they are unable to work or hold 
a job consistently. Because of the severe impediments associated with social phobia in terms of human 
interaction and social discourse, there is evidence that over half of all social phobics are single, 
divorced or separated. In the area of non-romantic relationships, shyness has been reported to correlate 
with low sociability and loneliness (Anderson and Harvey, 1988). More than 90% of a group of 
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patients with social phobia reported that their anxiety interfered significantly with occupational 
functioning, and 85% reported interference with academic functioning (Beidel et al., 1985). In a 
prospective study lasting over 30 years that compared outcome in shy versus non-shy boys, shy boys 
tended to enter a steady career later, hold lower status jobs, and have less occupational stability than 
non-shy boys (Caspi et al., 1988). Similarly, shy girls were less likely to have entered the work force 
or to have re-entered it after childbirth than were non-shy girls (Phillips and Bruch, 1988). Similar 
findings have been reported in Germany (Wittchen et al., 1998) and in France (Weiller et al., 1996). 
 Schneier et al. (1994) developed two new scales to estimate disability among social phobics: these 
are the Disability Profile (DP), a clinical rating instrument, and the Liebowitz Self-Rated Disability 
Scale (LSRDS). These scales were developed to augment the instruments available to assess disability 
in social phobia and potentially other psychiatric disorders. In 1993, Schneier et al. administered these 
scales to 32 patients with social phobia and 14 normal control subjects. They reported, consistent with 
other reports of social disability in social phobia, that social phobic patients reported moderate to 
severe impairment during their lives due to social anxiety and avoidance in education, employment, 
family relationships, marriage/romantic relationships, friendships/social network and other interests. 
Although the sample of patients is small, these results confirm other reports involving larger samples. 
 Those investigations which focused upon the impact of social phobia on the domains of everyday 
functioning, provide a confluence of strong empirical evidence, that social phobia is associated with 
significant disability and dysfunction in those afflicted. This, combined with the high prevalence and 
the chronic nature of social phobia, indicate it is a disorder of major public health significance. 
3. Comorbidity 
 Social phobia is often associated with other psychiatric disorders. One study found that 59% of 
people with the disorder also had simple phobias (such as fear of heights or spiders), 49% had panic 
disorder with agoraphobia, 19% were alcohol abusers, and 17% suffered from major depression. 
About 10 to 20% of patients in clinics for anxiety disorders suffer from social phobia; it is the most 
common secondary diagnosis among patients with another anxiety disorder. In clinical samples, 
comorbidity is extensive with major depression (40–85% current, 50–90% lifetime), dysthymia (20–
50%), other anxiety disorders (panic disorder, GAD, OCD), substance use disorders (alcohol 
abuse/dependence) especially in men. In epidemiologic samples, comorbidity is somewhat less 
extensive but patterns of comorbidity are very similar, e.g. major depression, panic disorder, GAD. 
 The symptoms overlap with those of panic disorder, and sometimes they are difficult to 
distinguish, as in cases where a person has a panic attack while giving a speech and afterward dreads 
all public speaking. The difference is that people with panic disorder do not fear scrutiny itself but the 
physical sensations associated with a feeling of being endangered and trapped. 
 Comorbidity of anxiety and mood disorders is common, and social phobia is no exception. Given 
the high degree of impairment associated with social phobia, especially in the area of interpersonal 
relationships, it is not surprising that many patients with social phobia develop secondary depressive 
symptoms. Alternatively, social phobia and depression may arise from a common vulnerability. 
‘Atypical depression’, which is characterised by hypersensitivity to rejection or criticism, has been 
noted to bear similarity to social phobia (Liebowitz et al., 1985a) and both appear to respond 
preferentially to monoamine oxidase inhibitors (MAOIs) as opposed to tricyclic antidepressants. As 
with alcoholism, the onset of social phobia usually precedes the onset of the mood disorder 
(Sanderson et al., 1990 and Schneier et al., 1992a). Additionally, suicidal ideation has been found to 
occur frequently among patients with social phobia, and the frequency of suicidal attempts may be 
higher than otherwise expected (Schneier et al., 1992a; Davidson et al., 1993a; Lepine and Lellouch, 
1995). 
 Major depression is often associated with social phobia, and family members of patients with 
social phobia have a high rate of depression. In one study people with both social phobia and panic 
disorder had a 95% risk of developing major depression. The order of cause and effect is not clear. 
Depression might lead to social withdrawal, or social withdrawal to depression; and the disorders 
might have common causes in heredity and upbringing. Depressed patients usually say that social 
phobia came first, but they are not necessarily right, since memories distorted by sadness and 
hopelessness may magnify normal reticence into a disabling disorder. For patients with a current 
diagnosis of social phobia, the co-occurrence of depressive episodes is frequent and extremely 
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disabling. Both symptomatic severity, social disability and suicide rates show that the comorbid 
condition is much more severe than ‘pure’ social phobia (Lecrubier and Weiller, 1997) 
 People with social phobias often use alcohol as self-medication. Alcoholics have nine times the 
rate of social phobia; one study found that about 15% of socially phobic men and women had had an 
alcohol problem at some time in their lives. Usually they must solve that problem before they can 
benefit from treatment for social phobia. If they have used alcohol (or an addictive illicit drug) long 
enough, the original symptoms of social phobia are obscured, and anxiety that reappears when they 
stop the drinking or drug use may be mistaken for withdrawal symptoms. Unfortunately, Alcoholics 
Anonymous and similar self-help groups for addicts are often ineffective for people with social 
phobias, because members are required to talk about themselves before an audience. 
4. Neurobiology of social phobia 
 Despite social phobia being a common psychiatric disorder (Kessler et al., 1994), the 
understanding of its pathophysiology is less than that for other disorders. Clues to the biology of this 
disorder come from one of several approaches; response to drug treatment, measurement of resting 
hormonal or neurotransmitter indices, pharmacological or behavioural challenges, and neuro-imaging 
studies, both structural and functional. 
4.1. Resting measurements 
 One strategy to explore the biology of social phobia is to determine hormonal levels, receptor 
concentrations, reuptake sites or other markers in the periphery which may reflect differences in the 
central nervous system (CNS) and provide insight into a biological mechanism. Contrasts between 
patients with social phobia and normal controls, or other patient populations, would presumably reflect 
on tonic differences independent of the presence or absence of a phobic stimulus. 
 A number of studies have examined the hypothalamic-pituitary-adrenal (Potts et al., 1991) or 
hypothalamic-thyroid axis (Tancer et al., 1990) and no significant differences have been detected 
among patients with social phobia and normal controls. 
 No differences have been reported in neuropeptide Y levels (Stein et al., 1996b) and serum 
interleukin-2 or soluble interleukin-2 receptors (Rapaport and Stein, 1994) in patients with social 
phobia compared to normal controls. Platelet 5HT2 receptor density is the same between patients with 
social phobia and normal controls (Chaterjee et al., 1997). There are also no differences in serotonin 
transporter densities in the platelets of patients with social phobia compared to those with panic 
disorder or normal controls using 3H-paroxetine binding (Stein et al., 1995). 
 Brain imaging studies of patients with social phobia have been performed in the resting state. 
Potts et al. (1994) examined magnetic resonance imaging (MRI) scans of brains in patients with social 
phobia compared to age- and sex-matched controls. No differences were found between the two 
groups in comparison of total cerebral, caudate, putamen or thalamic volumes. The patients with social 
phobia did have an age-related reduction in putamen volume that was greater than was observed for 
the normal control group, though the significance of this is not known.  
 Tiihonen et al. (1997) have examined dopamine reuptake sites using a 123I-labelled cocaine 
analogue and single photon emission computed tomography (SPECT) reporting that social phobics 
demonstrated lower dopamine reuptake densities in the striatal region, compared to normal controls. 
 Except for the differences in striatal dopamine reuptake sites using SPECT (Tiihonen et al., 1997), 
the measurement of differences between patients with social phobia and normal controls during a 
resting state has not been informative of positive differences. Since social phobia is a disorder that is 
symptomatic in response to the phobic stimulus, or thinking about the phobic stimulus, it is possible 
that challenge studies or dynamic measures may be more informative. 
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4.2. Dynamic measurements 
 Challenge studies are often used as a probe of endocrine or neurotransmitter functioning. These 
studies typically involve the administration of a chemical or a manoeuvre that may be anxiogenic in 
another anxiety disorder. Many of these challenges have been with compounds that elicit panic attacks 
in patients with panic disorder. 
 Liebowitz et al. (1985b) demonstrated that infusion of sodium lactate produced panic attacks in 10 
of 20 patients with panic disorder but only one of 15 in patients with social phobia. Inhalation of 35% 
CO2 (Papp et al., 1993) induced a panic response in 13/18 panic disorder patients, 6/20 social phobia 
patients and 1/23 control subjects. Infusion of epinephrine produced observable anxiety in only 1/11 
patients with social phobia (Papp et al., 1988). Social phobics, like patients with panic disorder, have 
a higher incidence of panic attacks following inhalation of 35% CO2 (Caldirola et al., 1997) or 
infusion of intravenous pentagastrin (Van Vliet et al., 1997a and McCann et al., 1997), but these 
findings are not specific to social phobia. When comparing 19, 11 and 19 patients with social phobia, 
panic disorder, or healthy controls, respectively, panic attacks were produced in 47% of social 
phobics, 64% of patients with panic disorder, and 11% of the normal controls (McCann et al., 1997). 
 A multi-probe study of serotonergic, noradrenergic or dopaminergic functioning in patients with 
social phobia, compared to normal controls, was reported by Tancer et al. (1994). In this study, a 
double-blind, placebo-controlled challenge was administered using fenfluramine (serotonergic probe), 
levo-DOPA (dopaminergic probe) or clonidine (noradrenergic probe). Social phobics demonstrated an 
augmented cortisol response to fenfluramine compared to normal controls. There were no differences 
between the patients with social phobia and the normal controls in response to the prolactin response 
to fenfluramine, GH or norepinephrine response to clonidine (oral administration), or the prolactin or 
eye-blink responses to levo-DOPA. 
 Social phobics appear to produce higher levels of norepinephrine in response to postural changes 
than do either normal controls or patients with panic disorder but the percentage of change is equal 
since social phobics had higher baseline levels of circulating norepinephrine (Stein et al., 1992). This 
finding obtained in a laboratory setting is not surprising given the nature of the illness. 
 To date however, there have been no published reports of pharmacological studies that specifically 
elicit symptoms of social phobia. 
 Our understanding of the biology of social phobia has advanced significantly over the past few 
years. Unfortunately, much of what has been discovered relates to systems in which social phobia does 
not differ from other anxiety disorders, or the responses of normal controls. Responses to medications 
has suggested involvement of the serotonergic and GABAergic systems, and perhaps the 
noradrenergic pathways as well. It is not clear though if it is these neurotransmitter systems that are 
dysregulated, or, if these are the neurotransmitter systems that are most amenable to manipulation with 
our currently available pharmacological agents. It is expected that measurements in a more dynamic 
setting, such as during exposure to phobic stimuli, should broaden our understanding of this common, 
but serious disorder. 
5. Pharmacological and cognitive treatment 
 Social phobia was once thought of as a personality trait, but the observation that serotonergic 
agents appear to be effective for its treatment (Lydiard, 1998) suggests that patients may have 
abnormal serotonergic neurotransmission within the central nervous system (Tancer et al., 1994).  
 The first step in pharmacotherapy of SP is the treatment of social phobia and adequate treatment of 
depression or other comorbid conditions is also an important consideration. Secondly, since social 
phobia is a chronic condition, choosing a treatment that can be well tolerated over long periods is an 
important aspect of enhancing compliance. The ideal outcome of achieving medication-free status may 
not be a reasonable goal for all patients and should certainly not be pursued at the expense of the 
patient’s well-being.  
 From a clinical perspective, the decision to treat anxiety disorders with medication involves an 
interplay between the experience and orientation of the clinician, the expectations and wishes of the 
patient, and the severity of the disorder affecting the patient. Severe, generalised social phobia is a 
serious disorder that merits early treatment intervention — including pharmacological therapy — to 
prevent or reverse the significant disability which accompanies untreated social phobia. Social phobia 
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commonly develops during the teenage years and may result in psychosocial development becoming 
arrested at this stage. After a response to treatment, a long period of ‘catching-up’ may be necessary as 
the gains are consolidated after the resumption of psychosocial development. Chronic treatment is 
therefore necessary in many cases and so it is essential that drug treatment is well tolerated. The 
monoamine oxidase inhibitors (MAOIs), benzodiazepines and, more recently, the selective serotonin 
reuptake inhibitors (SSRIs) have all shown promise as treatments for social phobia in terms of 
efficacy, but these different classes of drugs show important differences in tolerability, such as 
sedation, insomnia, sexual dysfunction, dependence liability and drug–drug interactions. 
5.1. Monoamine oxidase inhibitors 
 Non-selective monoamine oxidase inhibitors (MAOIs), both irreversible and reversible, inhibit the 
metabolism of 5HT, NE and DA. The irreversible MAOI, phenelzine, is effective in the treatment of 
social phobia (Liebowitz et al., 1992 and Versiani et al., 1992). Tranylcypromine (Versiani et al., 
1988) has shown efficacy for the treatment of social phobia in an open label trial. Phenelzine is the 
most extensively studied MAOI in the treatment of social phobia and its efficacy is well established 
(e.g. Gelertner et al., 1991, Liebowitz et al., 1992 and Versiani et al., 1992). There are less data on 
tranylcypromine but it might be expected to be effective in this condition. However, these agents 
require a restricted diet to avoid severe hypertensive crises after the ingestion of foods containing 
tyramine, and tolerability may be a problem over both the short and long term. Other adverse effects 
include insomnia, sexual dysfunction, postural hypotension, and weight gain. The reversible and 
selective MAOIs brofaromine (Van Vliet et al., 1992, Fahlen et al., 1995, Slaap et al., 1996 and Lott et 
al., 1997) and moclobemide (Versiani et al., 1992 and Versiani et al., 1996) have also demonstrated 
superiority to placebo in some, but not all (Noyes et al., 1997 and Schneier et al., 1998), double-blind 
studies of social phobia. At standard dosage moclobemide does not require dietary restriction, but at 
considerably higher doses, required by some patients, selectivity is lost. 
5.2. Beta blockers 
 These agents have performed poorly in controlled clinical trials of patients who mainly suffered 
from generalised subtype of social phobia (Liebowitz et al., 1992). However, anecdotal experience and 
controlled trials in anxious performers, suggest that they are effective for circumscribed symptoms of 
performance anxiety, especially if physiological tremor suppression is an advantage (e.g. violinist) 
(Bailly, 1996). Beta blockers have the advantages of as-needed use and of rarely impairing 
concentration or coordination and not inducing dependence. A non-selective beta blocker (affecting 
both the beta1-adrenergic receptors in the heart and the beta2-adrenergic receptors that mediate 
tremor), such as propranolol or nadolol, may in theory be more effective than a beta blocker selective 
for beta1-adrenergic receptors, such as atenolol or metoprolol, although this remains to be empirically 
tested (Schneier et al., 1992c). Before starting therapy with beta blockers, an electrocardiogram is 
often advisable to rule out the presence of atrioventricular (AV) block. Patients may then be instructed 
to try a test dose at home, both to ensure that the degree of beta blockade is sufficient and that 
untoward side effects will not develop during the performance. Beta blockers are contraindicated in 
patients with asthma and for use during athletic performance because beta blockers can diminish peak 
performances during activities that depend on high cardiac output. However it should be underlined 
that generalized social phobia, as currently defined by DSM-IV or ICD10, is not an indication for 
beta-blockers. 
5.3. Benzodiazepines and other anxiolytics 
 Both alprazolam and clonazepam have improved some patients in a number of open studies in 
social phobia (Lydiard et al., 1988, Reich et al., 1989, Munjack et al., 1990, Ontiveros and Fontaine, 
1990 and Reiter et al., 1990). A placebo-controlled trial of clonazepam achieved response rates 
approaching 80%, compared with 20–25% in placebo-treated patients (Davidson et al., 1993b). 
 Benzodiazepines can be effective symptom-suppressants for social phobia, but the relapse rates 
may be high (though it should be pointed out that controlled data are lacking) after treatment is 
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discontinued. Limitations for these agents are the lack of efficacy in depression, legal restriction for 
chronic use in some countries and their contraindication in patients who abuse alcohol or illicit drugs. 
In addition, treatment with benzodiazepines can be associated with the development of dependence. 
Since social phobia generally requires long-term therapy the role of benzodiazepines as a monotherapy 
for social phobia remains controversial. Buspirone, a non-benzodiazepine anxiolytic, has been used in 
social phobia (Clark and Agras, 1991 and Schneier et al., 1993). The results of double-blind trials do 
not support its usefulness (Van Vliet et al., 1997b). 
5.4. Serotonin selective reuptake inhibitors 
 Initial data from trials performed to examine the efficacy of the SSRIs have provided some 
evidence of efficacy, although comparisons between them are complicated by variations in study 
design and protocol. Efficacy in social phobia has been described in case reports for citalopram 
(Lepola et al., 1994 and Bouwer and Stein, 1998), open trials for fluoxetine (Schneier et al., 1992b; 
Van Ameringen et al., 1993) and double blind placebo controlled studies for fluvoxamine (Van Vliet et 
al., 1994), paroxetine (Stein et al., 1996a), sertraline (Katzelnick et al., 1995). 
 The results of these preliminary trials were encouraging but patient numbers were small and more 
evidence from larger trials was required. The first, large scale, placebo-controlled study to assess the 
efficacy of paroxetine in the most severe form of social phobia, generalised social phobia, has recently 
been completed in 183 patients meeting DSM-IV criteria for generalised social phobia. The main 
outcome measures were the mean change from baseline of the LSAS (Liebowitz Social Anxiety Scale) 
and a rating of ‘very much improved’ or ‘much improved’ (i.e. a score of 1 or 2) on the CGI (Clinical 
Global impression). Baseline assessments were comparable in the two groups. For both main outcome 
variables paroxetine was significantly more effective than placebo (Stein et al., 1998).  
 The responses to medications in the treatment of social phobia suggest some role for the 
serotonergic and GABAergic systems, indicated by responses to SSRIs and benzodiazepines, 
respectively. The role of noradrenergic systems alone is less clear. All of the MAOIs, reversible and 
irreversible, inhibit not only 5HT, but also NE and DA metabolism. There is no clinical data published 
on reboxetine in social phobia but evaluating the efficacy of treating social phobia with reboxetine, a 
selective NE reuptake inhibitor, might help to clarify the role of the noradrenergic system. In the only 
published report on the efficacy of venlafaxine, a dual 5HT/NE reuptake inhibitor, the mean dose was 
∼150 mg/day, a dose at which blood-pressure data suggests noradrenergic activity is present (Kelsey, 
1995). Patients included in this open-label trial had failed to respond or tolerate treatment with SSRIs 
and had a marked improvement on venlafaxine. 
5.5. Cognitive-behavioural treatments 
 Significant advances in the non-pharmacological treatment of social phobia have been made and 
scientifically validated. Several different cognitive behavioural treatment models have been 
developed, and it is not yet clear whether anyone is superior to the others (Lydiard and Falsetti, 1995). 
Substantial evidence for the effectiveness of various types of CBT in social phobia has accrued 
(Heimberg et al., 1998). It currently appears that CBT and pharmacotherapy are about equally 
effective in uncomplicated generalised and nongeneralised social phobic samples, although 
nongeneralised patients have higher remission rates with treatment (Lydiard and Falsetti, 1995). Most 
clinicians believe that combined CBT and medication treatment may be optimal treatment for many 
patients. Controlled studies designed to test this clinical impression are currently underway. 
5.6. Long-term treatment 
 Comparisons of drug and non-drug treatments are sparse and often vitiated by inadequate control 
of self-exposure in the drug-treated groups. Data concerning optimal strategies in a combined 
approach are almost non-existent as elaborate treatment designs are needed to explore this issue.  
 Efficacy has been established in acute treatment in studies of relatively short duration. Social 
phobia is however a long term illness and we need to know whether treatment in the short term 
produces a persisting effect or whether long term or repeated treatment is required to maintain 
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response. Few studies have followed patients up over a longer period to establish long term efficacy. 
However some evidence suggests that the gains made during short term treatment may increase and be 
maintained subsequently. 
 The need for long term treatment is indicated by a follow up of the patients included in the early 
short-term study of phenelzine and of moclobemide compared with placebo (Nutt and Montgomery, 
1996). Long term follow up of responders in this study recorded significantly more relapses on 
placebo than with moclobemide or phenelzine. When responders were randomised to continue active 
drug or placebo, relapse occurred within 2 months in between one half and one third of patients on 
placebo but not in those on active medication demonstrating that these drugs were associated with 
long term efficacy. The deterioration in response after randomisation at 16 weeks was gradual and 
persistent and therefore unlikely to have been a reflection of drug withdrawal effects (Versiani et al., 
1992).  
 Further evidence of long term efficacy has been obtained from the 4-year follow up of social 
phobia patients treated with moclobemide. In this study 93 patients with severe social phobia and 
various degrees of comorbid psychiatric disorder were treated openly with moclobemide for 2 months. 
Of these 59 continued treatment for 2 years and then entered a no treatment phase of at least a month. 
In the no treatment phase only seven patients remained well and the remainder deteriorated. When 
treatment was reintroduced for a further period of 2 years, patients again improved and there was a 
gradual decrease in severity scores. When the drug was discontinued or doses were reduced at the end 
of that period resurgence of symptoms was again seen in many patients (Versiani et al., 1997). 
 These results suggest that even if some of the gains are maintained, for full improvement the 
medication needs to be continued.  
 Another insight from this study was the poor outcome of patients with comorbid alcohol abuse. 
These patients generally did not improve during medication treatment, nor did they respond when 
switched at the end of the study to psychotherapy. This result underlines the need for early treatment 
to prevent the development of comorbid conditions. 
 Long-term treatment data are beginning to accrue and include both evaluations of continuing 
efficacy in short-term responders and prevention-of-relapse paradigms. As social phobia is a life-long 
disorder with major psychosocial implications, further long-term studies and follow-up studies are 
essential.  
 Meanwhile, guidelines have to rely on consensus opinion based on clinical practice. Most experts 
agree that milder forms of social phobia, or those restricted to particular situations (e.g. public 
speaking only) may respond well to nonpharmacologic interventions or to p.r.n. beta-blockers or p.r.n. 
benzodiazepines. For more severe cases, including patients who have the generalised subtype, p.r.n. 
medications are not indicated, but regular medication use is. It is not yet possible to specify which 
patients will respond best to regular pharmacotherapy, to cognitive-behavioural therapy, or to both. 
Given the relative availability and accessibility of these various treatments, however, it is likely that 
many patients will benefit from regular pharmacotherapy.  
 In this regard, the use of MAOIs — in particular phenelzine — is well-established as the ‘gold 
standard’ in the treatment of social phobia. However, because of dietary restrictions and other side-
effects frequently associated with their use (e.g. postural side-effects, weight gain, sexual side-effects), 
MAOIs are no longer considered by most experts to be a ‘first-line’ treatment for social phobia. 
Rather, given the strong and growing evidence for their utility, most expert clinicians now consider the 
SSRIs to be the pharmacological treatment-of-choice for this condition. Among the SSRIs, paroxetine 
has been the best-studied (e.g. Stein et al., 1998), though it is likely that other SSRIs will eventually 
display similar efficacy. Benzodiazepines may have a role to play, either as an adjunctive agent or for 
patients who are refractory to other treatments. Further research is needed on many aspects of the 
management of patients suffering from social phobia but major advances have been made in the last 
few years and considerable optimism is justified. 
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